The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NCFB). The US regulator cleared DPP1 ...

If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...

Bronchiectasis is a chronic lung condition in which your airways, or bronchi, widen permanently and become scarred. It may cause a persistent cough, large daily production of mucus (sputum or phlegm), ...

MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as ...

DPP‑1 inhibitors and long‑term macrolides appeared to effectively reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, with macrolides ...

It started out as a typical hot yoga class for Lavonda. The North Carolina resident was used to strenuous workouts, but on this day in 2008 she felt faint as she went through the sequence of poses.

Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...